PAVmed Inc. is a U.S.-based company that develops and commercializes innovative medical technologies. Its core product offerings include CarpX, a minimally invasive device designed for treating carpal tunnel syndrome, and EsoCheck, an advanced system for collecting esophageal cells to aid in the early identification of esophageal adenocarcinoma and Barrett's Esophagus (BE). The company's robust development pipeline further encompasses EsoGuard, a molecular diagnostic test utilizing esophageal DNA; EsoCure, an ablation device targeting dysplastic BE; PortIO, an implantable solution for intraosseous vascular access; NextFlo, a disposable infusion platform; and DisappEAR, a resorbable ear tube for pediatric use. Additional projects in their portfolio include NextCath and Caldus. Established in 2014 and headquartered in New York, New York, the firm initially operated under the name PAXmed Inc. before rebranding as PAVmed Inc. in April 2015.